Literature DB >> 21190500

Acetazolamide and sulfonamide allergy: a not so simple story.

Thomas E Kelly1, Peter H Hackett.   

Abstract

Allergies and adverse reactions to sulfonamide medications are quite common. Two distinct categories of drugs are classified as sulfonamides: antibiotics and nonantibiotics. The two groups differ in their chemical structure, use, and the rate at which adverse reactions occur. Cross-reactivity between the two groups has been implied in the past, but is suspect. Acetazolamide, from the nonantibiotic group, is routinely used in the prevention and treatment of high altitude issues and may not need to be avoided in individuals with a history of sulfonamide allergy. This review addresses the differences between the groups and the propensity for intergroup and intragroup adverse reactions based on the available literature. We also examine the different clinical presentations of allergy and adverse reactions, from simple cutaneous reactions with no sequelae through Stevens-Johnson syndrome and anaphylaxis, with risk for significant morbidity and mortality. We offer a systematic approach to determine whether acetazolamide is a safe option for those with a history of allergy to sulfonamides.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21190500     DOI: 10.1089/ham.2010.1051

Source DB:  PubMed          Journal:  High Alt Med Biol        ISSN: 1527-0297            Impact factor:   1.981


  9 in total

1.  Subtherapeutic Acetazolamide Doses as a Noninvasive Method for Assessing Medication Adherence.

Authors:  Aidan J Hampson; Jennifer R Schroeder; Kayla N Ellefsen; Luba Yammine; David H Epstein; Kenzie L Preston; Marilyn A Huestis; Christopher D Verrico
Journal:  Clin Pharmacol Ther       Date:  2020-07-11       Impact factor: 6.875

2.  Predicting PET Cerebrovascular Reserve with Deep Learning by Using Baseline MRI: A Pilot Investigation of a Drug-Free Brain Stress Test.

Authors:  David Y T Chen; Yosuke Ishii; Audrey P Fan; Jia Guo; Moss Y Zhao; Gary K Steinberg; Greg Zaharchuk
Journal:  Radiology       Date:  2020-07-14       Impact factor: 11.105

3.  A Pharmacokinetic Study Examining Acetazolamide as a Novel Adherence Marker for Clinical Trials.

Authors:  Aidan J Hampson; Shanna Babalonis; Michelle R Lofwall; Paul A Nuzzo; Phillip Krieter; Sharon L Walsh
Journal:  J Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.153

4.  Management of Cystoid Macular Edema in Retinitis Pigmentosa: A Systematic Review and Meta-Analysis.

Authors:  Chen Chen; Xia Liu; Xiaoyan Peng
Journal:  Front Med (Lausanne)       Date:  2022-05-16

5.  Acute pulmonary edema after a single oral dose of acetazolamide.

Authors:  I Vogiatzis; E Koulouris; A Sidiropoulos; C Giannakoulas
Journal:  Hippokratia       Date:  2013-04       Impact factor: 0.471

6.  Prophylactic effect of erythropoietin injection to prevent acute mountain sickness: an open-label randomized controlled trial.

Authors:  Kyoung Heo; Joong Koo Kang; Chang Min Choi; Moo Song Lee; Kyoung Woo Noh; Soon Bae Kim
Journal:  J Korean Med Sci       Date:  2014-02-27       Impact factor: 2.153

Review 7.  Non-Classical Inhibition of Carbonic Anhydrase.

Authors:  Carrie L Lomelino; Claudiu T Supuran; Robert McKenna
Journal:  Int J Mol Sci       Date:  2016-07-16       Impact factor: 5.923

8.  Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma.

Authors:  Katrin Lorenz; Joanna Wasielica-Poslednik; Katharina Bell; Giulia Renieri; Alexander Keicher; Christian Ruckes; Norbert Pfeiffer; Hagen Thieme
Journal:  PLoS One       Date:  2017-02-15       Impact factor: 3.240

9.  Identification of non-classical hCA XII inhibitors using combination of computational approaches for drug design and discovery.

Authors:  Mohammad M Al-Sanea; Garri Chilingaryan; Narek Abelyan; Grigor Arakelov; Harutyun Sahakyan; Vahram G Arakelov; Karen Nazaryan; Shaimaa Hussein; Gharam M Alazmi; Haifa E Alsharari; Waad M Al-Faraj; Faten S Alruwaili; Nouf Q Albilasi; Tahani S Alsharari; Abdulaziz A S Alsaleh; Turki M Alazmi; Atiah H Almalki; Nasser H Alotaibi; Mohamed A Abdelgawad
Journal:  Sci Rep       Date:  2021-07-30       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.